Lupin Shares Fall 2% After Citi Downgrade to Sell

Lupin Limited shares declined following a significant downgrade from Citi, according to reports. The brokerage firm cut its rating to 'Sell' and reduced its price target to Rs 2,050, reflecting a more cautious outlook on the pharmaceutical manufacturer's near-term prospects. The announcement indicated that Citi expects weaker US base-business sales and anticipates margin pressure ahead. Additionally, the brokerage reduced its FY27 earnings per share estimates by 14%, signaling a material revision to profitability expectations for the fiscal year ending March 2027. The downgrade also noted limited benefits anticipated from new product launches, which had potentially been viewed by some investors as a near-term growth driver.

From a market perspective, downgrades from major brokerages like Citi often trigger broader reassessment of pharmaceutical sector valuations, particularly for companies heavily exposed to the US market. The emphasis on margin pressure and weaker base-business sales reflects concerns about competitive intensity and pricing dynamics in core therapeutic areas. The 14% reduction in FY27 EPS estimates suggests structural headwinds rather than temporary setbacks, which typically warrants investor caution. However, technical indicators present mixed signals—while Lupin's chart pattern remains bearish overall, its relatively oversold RSI reading may suggest limited downside room in the very near term, though this does not negate the fundamental concerns outlined by Citi's analysts.

Source: Markets-Economic Times